Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.